FINWIRES · TerminalLIVE
FINWIRES

研究快讯:MKSI第一季度业绩及业绩指引远超市场预期,人工智能助力其业绩增长

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:MKSI公布的第一季度销售额为10.8亿美元(同比增长15%),超出市场普遍预期的10.5亿美元;非GAAP每股收益为2.30美元(同比增长35%),远高于市场普遍预期的2.05美元。毛利率为47.0%(环比增长60个基点,同比下降40个基点),营业利润率为21.8%(环比增长80个基点,同比增长160个基点),表明公司运营状况有所改善。我们仍然认为,这一强劲表现主要归功于人工智能基础设施需求的增长,这正日益惠及MKSI所有预计支出将加速增长的业务板块。第二季度业绩指引也远超市场预期,营收和每股收益的中值分别为12亿美元和2.90美元,而市场普遍预期分别为10.9亿美元和2.38美元。半导体业务(占销售额的43%)同比增长13%,较上一季度的9%有所加速;电子及封装业务(占30%)增长27%,特种工业业务(占27%)增长8%,均显示出持续复苏的态势。我们预计人工智能基础设施支出将在2026年下半年和2027年加速增长,管理层强调第一季度强劲的订单活动支撑了这一预期。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661